Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PDGFRB rearrangements status confers therapeutic sensitivity to Imatinib in patients with Myelodysplastic Syndromes.
The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor (PDGFR) gene rearrangements.
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.